ABOS News and Press, Acumen Pharmaceuticals Inc. From 08/15/22

Image source: The Motley Fool. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q2 2022 Earnings Call Aug 15, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Tran...

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Conference Call August 15, 2022 04:30 PM ET Company Participants John Woolford - Investor Relations, Westwicke Daniel O'Connell - President & Chief Executive Officer Eric Siemers - Chief Medical Officer ...

Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q2 GAAP EPS of -$0.25 in-line. Cash Balance. As of June 30, 2022, cash, cash equivalents and marketable securities totaled $209.9 million For further details see: Acumen Pharmaceuticals GAAP EPS of -$0.25 in-...

Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease (AD) Key methods and assay...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the Company wi...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the study of soluble amyloid beta oligomers (AβOs), toxic proteins that accumulate early ...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wi...

Gainers: Redbox Entertainment ( RDBX ) +100% . Nano Labs ( NA ) +86% . FaZe ( FAZE ) +42% . Koss Corporation ( KOSS ) +35% . SpringBig Holdings ( SBIG ) +31% . Infrastructure and Energy Alternatives ( IEA ) +31% . ...

Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing dis...